2023-01-24 08:00:00

Neuraxpharm completes its presence in Benelux by opening an affiliate in Brussels to cover Belgium and Luxembourg

Logo PR Newswire
PR Newswire

Belgium team to expand under Country Manager, Dr Pierre-Hervé Brun, providing CNS treatments to patients

BRUSSELS and DÜSSELDORF, Germany, Jan. 24, 2023 /PRNewswire/ -- Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces the establishment of Neuraxpharm Belgium to cover Belgium and Luxembourg, completing its presence in Benelux as it continues its expansion pathway in Europe.

Neuraxpharm's expansion into Belgium adds an additional country to the growing list of more than 20 countries where Neuraxpharm is widely recognized and established. Neuraxpharm Belgium will be based in Brussels and will distribute and market prescription brand Buccolam® (midazolam), which is indicated for the emergency treatment of children and adolescents with epileptic seizures, and Célocurine® (suxamethonium chloride) available in hospitals, an adjuvant of general anesthesia, both of which are already available on the Belgian market.

Neuraxpharm Belgium will develop its existing portfolio and plans to launch specialty products from the two branded product portfolios it acquired from Sanofi in July 2022. All products will be available for neurologists and psychiatrists, both in retail market, in hospitals and in pharmacies, for patients in Belgium and Luxembourg.

Dr. Pierre-Hervé Brun will be Country Manager for Neuraxpharm Belgium, alongside his current role as Country Manager for Neuraxpharm France. With 30 years in the pharmaceutical industry, Dr. Brun brings extensive experience in business development, market access & commercial operations management. His experience will be invaluable as Neuraxpharm accelerates its goal to become a global leader in the CNS field in Europe. Neuraxpharm plans to expand its Belgium team to support the significant opportunities in the Belgian market.

Dr. Jörg-Thomas Dierks, Chief Executive Officer of Neuraxpharm, said: "We are delighted by this strong and positive start to 2023 as we continue our expansion across Europe and increase our geographical presence. This is an exciting opportunity as we enter a new market to provide high quality medical solutions to Belgian patients."

Dr. Pierre-Hervé Brun, Country Manager of Neuraxpharm Belgium, added: "We are enthusiastic about this expansion as we further solidify Neuraxpharm as a key player in providing CNS treatment to patients and enhancing the wellbeing of those suffering from these disorders."

About the Group Neuraxpharm

Neuraxpharm is a leading European specialty pharmaceutical company focused on the treatment of central nervous system disorders (CNS) with a direct presence in over 20 countries and over 1000 employees. Backed by funds advised by Permira, Neuraxpharm has a unique understanding of the CNS market built over 35 years.

With its focus on CNS, Neuraxpharm develops and commercializes established brands, value added medicines, generics, Consumer Healthcare products, medical cannabis, beyond-the-pill solutions (digital health and medical devices) and orphan drugs and is continuously striving to offer a wide range of effective, high quality and affordable CNS treatment options in Europe.

Present with its products in more than 60 countries, Neuraxpharm distributes its products through an extensive sales force across Europe. The Company has a research hub and produces many of its pharmaceutical products and active pharmaceutical ingredients at its two production sites, Lesvi and Inke, in Spain.

For more information, please visit www.neuraxpharm.com

Cision View original content:https://www.prnewswire.co.uk/news-releases/neuraxpharm-completes-its-presence-in-benelux-by-opening-an-affiliate-in-brussels-to-cover-belgium-and-luxembourg-301728355.html

Logo PR Newswire
LONDON, Jan. 24, 2023 /PRNewswire/ -- A new era starts today as Covanta Europe becomes Encyclis and sets out its commitment to advancing Energy-from-Waste as...

Logo GlobeNewswire
SciencePress Release2023-01-24 06:00:00
Exclusive licensing and distribution agreement signed with Salus Pharmaceuticals in Lithuania, Estonia, Latvia, Croatia, Slovenia, Serbia, North Macedonia,...

Logo The Business Journals
Technology2023-01-23 18:39:59
The company is betting on Pittsburgh to ensure it'll continue the ability to grow its product.

Logo The Business Journals
Technology2023-01-23 11:16:13
The company, which was one of our Startups to Watch last year, has big plans in Europe.

Logo PR Newswire
LISHUI, China, Jan. 23, 2023 /PRNewswire/ -- CN Energy Group. Inc. (NASDAQ: CNEY) ("CNEY" or the "Company") today announced that it had established its...

Logo PR Newswire
SHENZHEN, China, Jan. 24, 2023 /PRNewswire/ -- Briocean Technology, the leading independent electronic component distributor, announces an expansion of its...

Logo GlobeNewswire
SciencePress Release2023-01-23 16:45:00
2022 TURNOVER OF 152.5M 15% CORE BUSINESS GROWTH AT 93M Growth of proprietary products reaching 18% of core revenues 1 Internationalization of the Group at...

Logo PR Newswire
HealthPress Release2023-01-23 12:00:00
PRINCETON, N.J., Jan. 23, 2023 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the...

Logo PR Newswire
HealthPress Release2023-01-23 13:18:00
NEW YORK and JERUSALEM, Jan. 23, 2023 /PRNewswire/ -- Immunyx Pharma, a developer of immune modulating therapies for neutrophil based diseases, announced it...

Logo NewsFileCorp
Press Release2023-01-23 14:37:00
Calgary, Alberta--(Newsfile Corp. - January 23, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to...

Logo GlobeNewswire
SciencePress Release2023-01-23 14:22:00
NEW HAVEN, Conn., Jan. 23, 2023 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (the Company or Bioasis ), a multi-asset rare and...

Logo EIN Presswire
HealthPress Release2023-01-23 09:00:00
contextflow Chief Commercial Officer Marcel Wassink and Medexprim CEO Medexprim and contextflow are proud to announce their partnership

Logo PR Newswire
HealthPress Release2023-01-23 14:00:00
VERNON, British Columbia, Jan. 23, 2023 /PRNewswire/ -- Doseology Sciences Inc. (CSE: MOOD) (OTCQB: DOSEF) (FSE: VU7) ("Doseology" or the "Company"), a life...

Logo GlobeNewswire
SciencePress Release2023-01-24 06:30:00
Press Release Nicox to Participate in Financial, Pharmaceutical Industry and Scientific Events in H1 2023 January 24, 2023 release at 7:30 am CET Sophia...

Logo GlobeNewswire
SciencePress Release2023-01-23 14:48:00
HAYWARD, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (Benitec or the Company), a development-stage, gene therapy-focused,...

Logo PR Newswire
HealthPress Release2023-01-23 14:00:00
MENLO PARK, Calif., Jan. 23, 2023 /PRNewswire/ -- BillionToOne, Inc., a next-generation molecular diagnostics company, is excited to announce the appointment...

Logo PR Newswire
HealthPress Release2023-01-23 13:24:00
SOLNA, Sweden, Jan. 23, 2023 /PRNewswire/ -- Hemcheck has received a follow-up order from its Spanish distributor, SDO Medical. The order concerns...

Logo GlobeNewswire
SciencePress Release2023-01-24 08:00:00
Helsinn and Immedica enter exclusive partnership for commercialisation of cancer supportive care products in core European markets LUGANO, Switzerland and...

Logo GlobeNewswire
SciencePress Release2023-01-23 12:00:00
RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced the company has entered into a...

Logo GlobeNewswire
SciencePress Release2023-01-24 06:15:00
Successful implementation of strategic decision to focus on anti-infectives and stronger than expected revenue lead to profitability earlier than anticipated...